VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has begun cell line development for its lead BiTAC® T-cell engager program, marking another step in preparing the company’s most advanced oncology candidate for future clinical development. The company announced it has selected ATUM, a U.S.-based contract research organization specializing in bioengineering and cell line development, to generate stable clonal cell lines using its proprietary Leap-In Transposase® technology.
The collaboration represents an important development milestone, supporting manufacturing, analytical development and nonclinical studies required before clinical testing. According to VERAXA, the partnership is intended to advance the candidate toward IND/CTA-enabling studies. The company’s BiTAC® platform is designed to improve the selectivity of T-cell engagers, potentially reducing toxicity associated with conventional approaches.
“We are excited to partner with ATUM as we advance our lead BiTAC®-TCE program toward the clinic,” said a VERAXA spokesperson. “Their expertise in cell line development using Leap-In Transposase® technology will help us generate high-quality stable cell lines to support our manufacturing and nonclinical development efforts.”
This development comes on the heels of VERAXA recently expanding its research facilities in Heidelberg, Germany, increasing laboratory capacity as multiple oncology programs move toward clinical development. The company’s focus on improving T-cell engager selectivity could have significant implications for cancer patients, as conventional T-cell engagers, while effective, often cause severe toxicities due to off-target activation. By engineering more selective engagers, VERAXA aims to expand the therapeutic window and potentially reduce adverse events.
For the biotech industry, this partnership underscores the growing importance of specialized contract research organizations in enabling early-stage development. ATUM’s Leap-In Transposase® technology offers a method for generating stable cell lines with high efficiency, which can accelerate timelines for producing therapeutic proteins. If successful, VERAXA’s approach could set a precedent for safer T-cell engager designs, influencing future research and development strategies in immuno-oncology.
Investors and stakeholders should note that forward-looking statements in this article involve risks and uncertainties, as detailed in the company’s filings with the SEC. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA. For full terms of use and disclaimers, visit http://IBN.fm/Disclaimer.
